Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects. 1980

H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata

The factor VIII response to DDAVP (1-deamino-8-D-arginine vasopressin) was examined in 6 healthy volunteers. Following intravenous DDAVP infusion, each subject showed a marked increase in factor VIII procoagulant activity (VIII:C), factor VIII related antigen (VIIIR:AG) and von Willebrand factor activity (VIIIR:WF). But there were differences among augmentation index of each activity. Further investigations were performed whether there was a qualitative abnormality in the factor VIII after DDAVP infusion. Between factor VIII activities before and after DDAVP, there was no difference in a thermostability of VIII:C in vitro, gel chromatographic pattern on Sepharose 2B or 4B, a precipitation with concanavalin A (Con A) and a recovery in cryoprecipitate. The increase of VIIIR:AG, however, was mostly brought about by the augmentation of relatively slowly migrating portion as demonstrated by crossed immunoelectrophoresis (CIE). From these results it was assumed that there was no remarkable abnormalities in the factor VIII after DDAVP administration, and the elevated factor VIII could function efficiently in vivo. The findings in cryoprecipitation showed that DDAVP could be applied to blood donation for the preparation of cryoprecipitate.

UI MeSH Term Description Entries
D007123 Immunoelectrophoresis, Two-Dimensional Immunoelectrophoresis in which a second electrophoretic transport is performed on the initially separated antigen fragments into an antibody-containing medium in a direction perpendicular to the first electrophoresis. Immunoelectrophoresis, Crossed,Immunoelectrophoresis, 2-D,Immunoelectrophoresis, 2D,2-D Immunoelectrophoresis,2D Immunoelectrophoresis,Crossed Immunoelectrophoresis,Immunoelectrophoresis, 2 D,Immunoelectrophoresis, Two Dimensional,Two-Dimensional Immunoelectrophoresis
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003894 Deamino Arginine Vasopressin A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. Desmopressin,Vasopressin, Deamino Arginine,1-Deamino-8-D-arginine Vasopressin,1-Desamino-8-arginine Vasopressin,Adiuretin,Adiuretin SD,Apo-Desmopressin,DDAVP,Desmogalen,Desmopressin Acetate,Desmopressin Monoacetate,Desmopressin Monoacetate, Trihydrate,Desmopressine Ferring,Desmospray,Desmotabs,Minirin,Minurin,Nocutil,Octim,Octostim,Acetate, Desmopressin,Arginine Vasopressin, Deamino,Ferring, Desmopressine,Monoacetate, Desmopressin,Monoacetate, Trihydrate Desmopressin,Trihydrate Desmopressin Monoacetate,Vasopressin, 1-Deamino-8-D-arginine,Vasopressin, 1-Desamino-8-arginine
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D014841 von Willebrand Factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor. Factor VIII-Related Antigen,Factor VIIIR-Ag,Factor VIIIR-RCo,Plasma Factor VIII Complex,Ristocetin Cofactor,Ristocetin-Willebrand Factor,von Willebrand Protein,Factor VIII Related Antigen,Factor VIIIR Ag,Factor VIIIR RCo,Ristocetin Willebrand Factor

Related Publications

H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
January 1984, La Ricerca in clinica e in laboratorio,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
April 1976, International journal of clinical pharmacology and biopharmacy,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
January 1985, British journal of haematology,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
August 1981, Irish journal of medical science,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
August 1985, Revista medica de Chile,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
November 1989, Ugeskrift for laeger,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
December 2000, British journal of haematology,
H Takahashi, and M Itoh, and I Kobayashi, and N Sakuragawa, and A Shibata
January 1990, Haemostasis,
Copied contents to your clipboard!